Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
Key Highlights
- ➤$149 million cash, runway targeted into H2 2028 after operating-model realignment
- ➤.HEAL-101 edited APOC3 up to 70%, reducing triglycerides 76% in mice
- ➤.HEAL-201 reduced plasma PCSK9 more than 90% in humanized liver mice
- ➤Nine-month revenue fell to $19.9 million from $67.4 million
- ➤Nine-month net loss widened to $101.1 million from $41.3 million
- ➤Headcount expected to fall up to 70% during 2026 and 2027
Expert Statements
André Choulika, Co-founder and Chief Executive Officer of Cellectis
“Since September, our teams have been fully committed to our new in vivo gene editing chapter, and the expanded preclinical data we presented at ESGCT for .HEAL-101 reinforce our conviction”
André Choulika, Co-founder and Chief Executive Officer of Cellectis
“After a single administration, .HEAL-101 edited the human APOC3 gene at rates of up to 70% in a humanized liver model, with editing restricted to the liver, and consistently reduced triglycerides by 76% in a disease model. These results support the continued development of .HEAL-101, and the initiation of an investigator-initiated trial in China is on track with the goal of delivering first clinical data for .HEAL-101 in the second half of 2027.”
* .HEAL-101 achieved up to 70% in vivo APOC3 editing with liver-restricted activity and confirmed 76% triglyceride reduction in murine models (ESGCT 2026); Phase 1 IIT in China on track for initiation, with preliminary clinical data expected in H2 2027 * .HEAL-201 achieved >90% reduction in plasma PCSK9 in a humanized liver mouse model; preliminary clinical data expected in H1 2028 * Cash, cash equivalents and fixed-term deposits of $149 million as of September 30, 2026(1); realignment of the operating model targeting cash runway into H2 2028 * Conference call scheduled for November 13 at 8 a.m. ET / 2 p.m. CET NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today reported financial results for the third quarter 2026 ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.